# Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

Source: https://onco.cc/trials/nct07253896/  
OnCo record `nct07253896` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.

## Summary

Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab is a phase 2, interventional study registered as NCT07253896 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 40 participants, started 2024-01-03 and due to reach its primary completion in 2026-01-03. Interventions recorded: AK104 and cetuximab or bevacizumab and FOLFIRI. Conditions listed: Safety. Primary outcome: objective response rate. Colorectal eligibility wording from the registry: "Metastatic colorectal adenocarcinoma confirmed by histology or cytology". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07253896
- Phase: 2
- Setting: Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab as Second-line Treatment in MSS Type Metastatic Colorectal Cancer Based on RAS Gene Status
- Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07253896: https://clinicaltrials.gov/study/NCT07253896

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07253896.json